Yesterday, 4 senators introduced a bill on the Senate floor that would allow HHS to block drug price increases that it deems as “excessive.”
Yesterday, Senators Richard Blumenthal, D-Connecticut, Kamala Harris, D-California, Amy Klobuchar, D-Minnesota, and Jeff Merkley, D-Oregon, introduced a bill on the Senate floor, S. 3754, that would allow HHS to block drug price increases that it deems as “excessive.”
The bill, dubbed “A bill to prohibit price gouging in the sale of drugs,” is just the latest in a series of actions that Congressmen and the government alike have taken to address high drug prices.
In May 2018, the Trump administration released the “American Patients First” blueprint which contained 4 main strategies for decreasing drug prices, including increased competition, better negotiation, incentives for lower list prices, and reducing out-of-pocket costs. Since the release of the blueprint, the FDA approved more generic drugs in July 2018 than in any single month in its history.
Additionally, in July 2018 the FDA also released its Biosimilar Action Plan. The plan sought to improve the efficiency of the biosimilar development and approval process and support market competition through the reduction of anti-competitive practices that unfairly delay market entry. In 2018 alone, the FDA has approved 6 biosimilars of rituximab, epoetin alfa, adalimumab, pegfilgrastim, and filgrastim.
The administration took further action in October 2018 when HHS Secretary Alex Azar proposed requiring drug companies to include the list price of a drug paid for by Medicare or Medicaid in direct-to-consumer television advertising.
The proposal was met with pushback from industry trade group, Pharmaceutical Research and Manufacturers of America (PhRMA), when it announced that instead of including the list price within the advertisement, it would launch a “new platform that would provide patients, caregivers, and providers with cost and financial assistance information for brand-name medicines, as well as other patient support resources.” PhRMA also made clear to HHS that if such a requirement was made, it would raise significant legal questions, including First Amendment concerns.
Though 2018 has seen significant focus on reducing drug prices, more action is sure to come in 2019. According to Reuters, Democrat House of Representatives leader Nancy Pelosi, D-California, has promised to continue to work to tackle the issue of high drug prices when the newly-elected House is sworn in in January 2019.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.